文献速递认知障碍与痴呆

质子泵抑制剂的累积使用与痴呆风险:社区动脉粥样硬化风险研究

Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.
PubMed 文献 · Neurology · 2023-08-09

该研究基于社区队列ARIC,评估第5次访视时当前及累积质子泵抑制剂(PPI)使用与痴呆风险的关系。共纳入5,712名无痴呆参与者,中位随访5.5年,新发痴呆585例。当前使用PPI与痴呆风险无显著关联(HR 1.1, 95%CI 0.9-1.3);累积使用超过4.4年者风险升高33%(HR 1.3, 95%CI 1.0-1.8),较短时间使用无显著关联。

要点

  • 第5次访视时当前使用PPI与后续痴呆风险无显著关联(HR 1.1, 95%CI 0.9-1.3)。
  • 累积使用PPI超过4.4年者痴呆风险较未使用者升高33%(HR 1.3, 95%CI 1.0-1.8)。
  • 累积使用PPI不足4.4年者与痴呆风险无显著关联。

核心结论

  • 45岁及以上人群处方使用PPI超过4.4年与新诊断痴呆发病率升高相关(证据等级Class III)。
  • 第5次访视时当前使用PPI与后续痴呆风险无显著关联。
  • 未来需要研究以理解累积PPI使用与痴呆发生之间的可能通路。

研究设计与样本

  • 研究基于社区队列ARIC,纳入从入组(1987-1989年)至2017年的参与者。
  • 以第5次访视(2011-2013年)为基线,因该次访视首次出现PPI使用普遍。
  • PPI使用通过第1至第5次访视的视觉药物清单及2006-2011年年度电话报告评估。
  • 暴露分为第5次访视时当前使用及第5次访视前累积使用时长(0天、1天-2.8年、2.8-4.4年、>4.4年)。
  • 采用Cox比例风险模型,校正人口学特征、合并症及其他药物使用。

主要发现

  • 共纳入5,712名第5次访视时无痴呆的参与者,平均年龄75.4±5.1岁,22%为黑人,58%为女性。
  • 中位随访5.5年,期间新发痴呆585例。
  • 累积PPI使用最短112天,最长20.3年。
  • 第5次访视时使用PPI者较未使用者后续痴呆风险无显著升高(HR 1.1, 95%CI 0.9-1.3)。
  • 第5次访视前累积使用PPI超过4.4年者较未使用者痴呆风险升高33%(HR 1.3, 95%CI 1.0-1.8);较短时间使用无显著关联。

关键数值与推荐

  • 当前使用PPI与痴呆风险:HR 1.1(95%CI 0.9-1.3),无显著关联。
  • 累积使用PPI >4.4年与痴呆风险:HR 1.3(95%CI 1.0-1.8),风险较未使用者升高33%。
  • 证据等级:Class III,即45岁及以上人群处方使用PPI超过4.4年与新诊断痴呆发病率升高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需要研究以理解累积PPI使用与痴呆发生之间的可能通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Studies on the association between proton pump inhibitor (PPI) use and dementia report mixed results and do not examine the impact of cumulative PPI use. We evaluated the associations between current and cumulative PPI use and risk of incident dementia in the Atherosclerosis Risk in Communities (ARIC) Study. METHODS: These analyses used participants from a community-based cohort (ARIC) from the time of enrollment (1987-1989) through 2017. PPI use was assessed through visual medication inventory at clinic visits 1 (1987-1989) to 5 (2011-2013) and reported annually in study phone calls (2006-2011). This study uses ARIC visit 5 as baseline because this was the first visit in which PPI use was common. PPI use was examined 2 ways: current use at visit 5 and duration of use before visit 5 (from visit 1 to 2011, exposure categories: 0 day, 1 day-2.8 years, 2.8-4.4 years, >4.4 years). The outcome was incident dementia after visit 5. Cox proportional hazard models were used, adjusted for demographics, comorbid conditions, and other medication use. RESULTS: A total of 5,712 dementia-free participants at visit 5 (mean age 75.4 ± 5.1 years; 22% Black race; 58% female) were included in our analysis. The median follow-up was 5.5 years. The minimum cumulative PPI use was 112 days, and the maximum use was 20.3 years. There were 585 cases of incident dementia identified during follow-up. Participants using PPIs at visit 5 were not at a significantly higher risk of developing dementia during subsequent follow-up than those not using PPIs (hazard ratio (HR): 1.1 [95% confidence interval (CI) 0.9-1.3]). Those who used PPIs for >4.4 cumulative years before visit 5 were at 33% higher risk of developing dementia during follow-up (HR: 1.3 [95% CI 1.0-1.8]) than those reporting no use. Associations were not significant for lesser durations of PPI use. DISCUSSION: Future studies are needed to understand possible pathways between cumulative PPI use and the development of dementia. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the use of prescribed PPIs for >4.4 years by individuals aged 45 years and older is associated with a higher incidence of newly diagnosed dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Northuis CA, Bell EJ, Lutsey PL, et al. Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study. Neurology. 2023. PMID: 37558503. doi:10.1212/WNL.0000000000207747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。